首页> 外文期刊>EBioMedicine >Comprehensive molecular and immunological characterization of hepatocellular carcinoma
【24h】

Comprehensive molecular and immunological characterization of hepatocellular carcinoma

机译:肝细胞癌的全面分子和免疫学表征

获取原文
           

摘要

Background Hepatocellular carcinoma (HCC) is a heterogeneous disease with various etiological factors, and ranks as the second leading cause of cancer-related mortality worldwide due to multi-focal recurrence. We herein identified three major subtypes of HCC by performing integrative analysis of two omics data sets, and clarified that this classification was closely correlated with clinicopathological factors, immune profiles and recurrence patterns. Methods In the test study, 183 tumor specimens surgically resected from HCC patients were collected for unsupervised clustering analysis of gene expression signatures and comparative analysis of gene mutations. These results were validated by using genome, methylome and transcriptome data of 373 HCC patients provided from the Cancer Genome Atlas Network. In addition, omics data were obtained from pairs of primary and recurrent HCC. Findings Comprehensive molecular evaluation of HCC by multi-platform analysis defined three major subtypes: (1) mitogenic and stem cell-like tumors with chromosomal instability; (2) CTNNB1 -mutated tumors displaying immune suppression; and (3) metabolic disease-associated tumors, which included an immunogenic subgroup characterized by macrophage infiltration and favorable prognosis. Although genomic and epigenomic analysis explicitly distinguished between HCC with intrahepatic metastasis (IM) and multi-centric HCC (MC), the phenotypic similarity between the primary and recurrent tumors was not correlated to the IM/MC origin, but to the classification. Interpretation: Identification of these HCC subtypes provides further insights into patient stratification as well as presents opportunities for therapeutic development. Fund Ministry of Education, Culture, Sports, Science and Technology of Japan (16H02670 and 18K19575), Japan Agency for Medical Research and Development (JP15cm0106064, JP17cm0106518, JP18cm0106540 and JP18fk0210040).
机译:背景肝细胞癌(HCC)是一种具有多种病因的异质性疾病,由于多灶性复发,被列为全球第二大癌症相关死亡的主要原因。我们通过对两个组学数据集进行综合分析,确定了HCC的三种主要亚型,并阐明该分类与临床病理因素,免疫谱和复发模式密切相关。方法在试验研究中,收集了183例从HCC患者手术切除的肿瘤标本,用于基因表达特征的无监督聚类分析和基因突变的比较分析。这些结果通过使用癌症基因组图谱网络提供的373例HCC患者的基因组,甲基化组和转录组数据进行了验证。此外,从成对的原发性和复发性肝癌中获得了组学数据。研究结果通过多平台分析对HCC进行全面的分子评估,确定了三种主要的亚型:(1)有染色体不稳定的有丝分裂和干细胞样肿瘤; (2)CTNNB1突变的肿瘤表现出免疫抑制作用; (3)与代谢疾病有关的肿瘤,包括以巨噬细胞浸润和预后良好为特征的免疫原性亚组。尽管基因组和表观基因组学分析明确区分了肝内转移性肝癌(IM)和多中心性肝癌(MC),但原发性和复发性肿瘤之间的表型相似性与IM / MC的起源无关,而与分类有关。解释:这些HCC亚型的鉴定为患者分层提供了进一步的见识,并为治疗发展提供了机会。日本教育,文化,体育,科学和技术部(16H02670和18K19575),日本医学研究与发展局(JP15cm0106064,JP17cm0106518,JP18cm0106540​​和JP18fk0210040)基金。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号